Welcome to Industry Focus, the podcast that dives into a different sector of the stock market every day.

It's November 30th and we're talking health care.

I'm Michael Douglas, filling in for Christine Hardust,. I've got Todd Campbell on the line.

Todd, good to see you.

Hey Michael, how are you?

I'm pretty good.

It's been a good week so far.

And a lot of news and health care.

So let's hop right in and we figured today would be just

kind of a quick take on a number of different stories let's let's start

with amicus first yeah unfortunately that some of the news that we're covering this week isn't, it's always nice when we can be

the bearer of good news, right?

It's a mixed bag this time.

Yeah, it's a little bit of a mixed bag this week.

Unfortunately, we got two stocks that are reminding us as investors that we need to

diversify especially when we're talking about biotech and one of the stocks

that you know we're talking about here is amicus and amicus is a rare disease

rare a rare disease drug developer that already has one drug that's on the market

Galifold for use in a very rare condition called fabry disease. But that drug is only

available in Europe right now. And many investors had hoped that it would soon become available in the United States.

But instead, the FDA is requiring another trial,

and Amicus has guided that that's a good three-year delay

...